688197 首药控股
已收盘 07-30 15:00:01
资讯
新帖
简况
首药控股-U涨5.05% 政策催化与资金博弈共振
智选洞察 · 02:10
首药控股-U涨5.05% 政策催化与资金博弈共振
首药控股获融资买入0.13亿元,近三日累计买入0.41亿元
金融界 · 07-26
首药控股获融资买入0.13亿元,近三日累计买入0.41亿元
华创医药投资观点&研究专题周周谈·第136期:高血压创新药是一笔好生意吗?
华创证券 · 07-25
华创医药投资观点&研究专题周周谈·第136期:高血压创新药是一笔好生意吗?
首药控股-U股价下跌4.10% 自主研发KRAS抑制剂临床进展顺利
金融界 · 07-21
首药控股-U股价下跌4.10% 自主研发KRAS抑制剂临床进展顺利
首药控股:SY-5933临床进展顺利
21世纪经济报道 · 07-21
首药控股:SY-5933临床进展顺利
每周股票复盘:首药控股(688197)因收盘价格涨幅达15%首次上榜龙虎榜
证券之星 · 07-19
每周股票复盘:首药控股(688197)因收盘价格涨幅达15%首次上榜龙虎榜
7月17日首药控股(688197)龙虎榜数据:机构净买入5535.28万元,北向资金净买入655.83万元
证券之星 · 07-17
7月17日首药控股(688197)龙虎榜数据:机构净买入5535.28万元,北向资金净买入655.83万元
首药控股-U涨5.26% 医保新政释放利好叠加资金流入
智选洞察 · 07-17
首药控股-U涨5.26% 医保新政释放利好叠加资金流入
科创成长层改革推进 券商系统升级及风险揭示书签署有序展开
DoNews · 07-16
科创成长层改革推进 券商系统升级及风险揭示书签署有序展开
首药控股-U涨5.41% 政策红利与估值压力共振
智选洞察 · 07-01
首药控股-U涨5.41% 政策红利与估值压力共振
首药控股-U早盘跌5.02%创月新低 资金持续流出压制股价
智选洞察 · 06-26
首药控股-U早盘跌5.02%创月新低 资金持续流出压制股价
首药控股-U06月24日主力净流出259.7万元 散户资金买入
市场透视 · 06-24
首药控股-U06月24日主力净流出259.7万元 散户资金买入
首药控股-U06月23日主力净流入666.6万元 散户资金抛售
市场透视 · 06-23
首药控股-U06月23日主力净流入666.6万元 散户资金抛售
首药控股:拟使用自有资金支付募投项目部分款项并以募集资金等额置换
公司公告 · 06-20
首药控股:拟使用自有资金支付募投项目部分款项并以募集资金等额置换
首药控股-U06月19日遭主力抛售539.9万元
市场透视 · 06-19
首药控股-U06月19日遭主力抛售539.9万元
首药控股:ALK-TKI双代布局 SY-707上市在即
长城国瑞证券有... · 06-19
首药控股:ALK-TKI双代布局 SY-707上市在即
长城国瑞证券给予首药控股增持评级:ALK-TKI双代布局,SY-707上市在即
每日经济新闻 · 06-19
长城国瑞证券给予首药控股增持评级:ALK-TKI双代布局,SY-707上市在即
首药控股-U06月18日主力净流出27.9万元 散户资金买入
市场透视 · 06-18
首药控股-U06月18日主力净流出27.9万元 散户资金买入
首药控股:公司高选择性RET抑制剂SY-5007关键性注册Ⅲ期临床试验的主要疗效指标超过预设值
证券之星 · 06-17
首药控股:公司高选择性RET抑制剂SY-5007关键性注册Ⅲ期临床试验的主要疗效指标超过预设值
A股创新药企:多家公司研发人员占比突破79%
21世纪经济报道 · 06-17
A股创新药企:多家公司研发人员占比突破79%
加载更多
公司概况
公司名称:
首药控股(北京)股份有限公司
所属行业:
医药制造业
上市日期:
2022-03-23
主营业务:
首药控股(北京)股份有限公司的主营业务是肿瘤和糖尿病药物的研发。公司的主要产品是技术开发及服务。
发行价格:
39.90
{"stockData":{"symbol":"688197","market":"SH","secType":"STK","nameCN":"首药控股","latestPrice":48.02,"timestamp":1753858801000,"preClose":45.16,"halted":0,"volume":5902997,"delay":0,"changeRate":0.0633,"floatShares":64004900,"shares":149000000,"eps":-1.408,"marketStatus":"已收盘","change":2.86,"latestTime":"07-30 15:00:01","open":45.1,"high":52,"low":44.06,"amount":287000000,"amplitude":0.1758,"askPrice":48.06,"askSize":7,"bidPrice":48.02,"bidSize":180,"shortable":0,"etf":0,"ttmEps":-1.408,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753925400000},"marketStatusCode":5,"adr":0,"adjPreClose":45.16,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753839000000,1753846200000],[1753851600000,1753858800000]],"highLimit":49.68,"lowLimit":40.64,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":148719343,"isCdr":false,"pbRate":9.42,"roa":"--","roe":"--","epsLYR":-1.43,"committee":0.54902,"marketValue":7142000000,"turnoverRate":0.0922,"status":0,"afterMarket":{"amount":0,"volume":0,"close":48.02,"buyVolume":0,"sellVolume":0,"time":1753860838019,"indexStatus":"已收盘 07-30 15:30:00","preClose":45.16},"floatMarketCap":3074000000},"requestUrl":"/m/hq/s/688197","defaultTab":"news","newsList":[{"id":"2555109512","title":"首药控股-U涨5.05% 政策催化与资金博弈共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2555109512","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555109512?lang=zh_cn&edition=full","pubTime":"2025-07-30 10:10","pubTimestamp":1753841441,"startTime":"0","endTime":"0","summary":"首药控股-U今日盘中表现强劲,截至10点10分,股价报47.44元,上涨5.05%。政策催化与资金博弈共振首药控股-U近期股价异动主要受政策与事件双重驱动。但截至7月30日,市净率仍高达9.3倍,远超行业平均水平,部分资金选择在SY-3505临床数据揭盲前兑现收益,导致股价振幅达7.53%。SY-707若年内获批,预计峰值销售或突破15亿元,而SY-3505二期数据若达标,潜在市场空间可达百亿级别。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730101045a6c8bf0e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250730101045a6c8bf0e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2554058797","title":"首药控股获融资买入0.13亿元,近三日累计买入0.41亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554058797","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554058797?lang=zh_cn&edition=full","pubTime":"2025-07-26 08:02","pubTimestamp":1753488157,"startTime":"0","endTime":"0","summary":"7月25日,沪深两融数据显示,首药控股获融资买入额0.13亿元,居两市第1130位,当日融资偿还额0.15亿元,净卖出172.74万元。最近三个交易日,23日-25日,首药控股分别获融资买入0.13亿元、0.14亿元、0.13亿元。融券方面,当日融券卖出0.00万股,净卖出0.00万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072608160094bb90a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072608160094bb90a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2554716357","title":"华创医药投资观点&研究专题周周谈·第136期:高血压创新药是一笔好生意吗?","url":"https://stock-news.laohu8.com/highlight/detail?id=2554716357","media":"华创证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554716357?lang=zh_cn&edition=full","pubTime":"2025-07-26 00:00","pubTimestamp":1753459200,"startTime":"0","endTime":"0","summary":"本周行情回顾本周,中信医药指数上涨1.97%,跑赢沪深300指数0.28个百分点,在中信30个一级行业中排名第19位。本周涨幅前十名股票为海特生物、振东制药、塞力医疗、辰欣药业、仁度生物、康芝药业、易明医药、苑东生物、康泰医学、迈普医学。本周跌幅前十名股票*ST苏吴、永安药业、力生制药、首药控股-U、泽璟制药-U、科兴制药、信立泰、上海谊众、浙江震元、神州细胞。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726164141a4647f7b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726164141a4647f7b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688197","159992","688266","603367","688513","688136","159377","600200","688091","BK0239","688193","399275","603716","688520"],"gpt_icon":0},{"id":"2553403414","title":"首药控股-U股价下跌4.10% 自主研发KRAS抑制剂临床进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2553403414","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553403414?lang=zh_cn&edition=full","pubTime":"2025-07-22 00:00","pubTimestamp":1753113606,"startTime":"0","endTime":"0","summary":"首药控股-U股价报47.95元,较前一交易日下跌2.05元,跌幅4.10%。首药控股-U属于生物制品板块,专注于创新药研发。公司自主研发的KRAS抑制剂SY-5933在临床前研究中表现出显著的抗肿瘤活性,对KRAS突变阳性的肿瘤细胞生长有明显抑制作用。此外,SY-5933与FAK抑制剂SY-707联用可协同抑制肿瘤细胞增殖,目前联合用药方案的临床试验已正式启动并有序入组。7月21日,首药控股-U主力资金净流入53.44万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722001034954b5977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722001034954b5977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2553547440","title":"首药控股:SY-5933临床进展顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=2553547440","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553547440?lang=zh_cn&edition=full","pubTime":"2025-07-21 10:00","pubTimestamp":1753063200,"startTime":"0","endTime":"0","summary":"南方财经7月21日电,首药控股在2025年6月2日至7月18日的调研中表示,公司自主研发的KRAS(G12C)抑制剂SY-5933在临床前研究中表现出显著的抗肿瘤活性,对KRAS(G12C)突变阳性的肿瘤细胞生长有明显抑制作用。2024年内完成的I期临床研究表明,SY-5933在复发/难治性KRAS(G12C)突变的肿瘤患者中展现了良好的药代动力学参数和抗肿瘤活性,患者耐受性良好。公司还发现SY-5933与FAK抑制剂SY-707联用可协同抑制肿瘤细胞增殖,增强对肿瘤生长的抑制作用。目前,联合用药方案的临床试验已正式启动并有序入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072110010797ade36b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072110010797ade36b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2552417261","title":"每周股票复盘:首药控股(688197)因收盘价格涨幅达15%首次上榜龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2552417261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552417261?lang=zh_cn&edition=full","pubTime":"2025-07-20 05:05","pubTimestamp":1752959115,"startTime":"0","endTime":"0","summary":"截至2025年7月18日收盘,首药控股报收于50.0元,较上周的39.98元上涨25.06%。本周,首药控股7月18日盘中最高价报50.17元,股价触及近一年最高点。首药控股当前最新总市值74.36亿元,在化学制药板块市值排名75/150,在两市A股市值排名2219/5149。本周关注点交易信息汇总:首药控股因收盘价格涨幅达到15%首次上榜龙虎榜交易信息汇总沪深交易所2025年7月17日公布的交易公开信息显示,首药控股因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072000001236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2552073971","title":"7月17日首药控股(688197)龙虎榜数据:机构净买入5535.28万元,北向资金净买入655.83万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552073971","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552073971?lang=zh_cn&edition=full","pubTime":"2025-07-17 17:14","pubTimestamp":1752743666,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2025年7月17日公布的交易公开信息显示,首药控股因有价格涨跌幅限制的日收盘价格涨幅达到15%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2025年7月17日收盘,首药控股报收于47.0元,上涨15.54%,换手率7.6%,成交量4.86万手,成交额2.13亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入5535.28万元,北向资金合计净买入655.83万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071700026761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2552778471","title":"首药控股-U涨5.26% 医保新政释放利好叠加资金流入","url":"https://stock-news.laohu8.com/highlight/detail?id=2552778471","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552778471?lang=zh_cn&edition=full","pubTime":"2025-07-17 10:33","pubTimestamp":1752719589,"startTime":"0","endTime":"0","summary":"首药控股-U股价大幅上涨,最新价42.82元/股,涨幅5.26%。资金博弈与政策预期交织下的股价波动首药控股-U近期净流入受多重短期因素影响。此外,公司市净率高达8.36倍,显著高于行业均值,叠加动态市盈率-30.29倍的未盈利特征,加剧估值分歧。2025年医保新政虽释放创新药支持信号,但公司商业化能力尚未验证,部分资金选择短期获利了结。研发转化效率与流动性预期重构估值逻辑首药控股-U的长期价值锚定于研发管线转化及政策红利兑现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717103315a6aea440&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717103315a6aea440&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551119280?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作,并修订相关指南,新增《科创板科创成长层企业股票投资风险揭示书必备条款》,明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作,包括完成风险揭示书签署及系统准备,给予投资者充分阅读时间,并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日,上交所举办专题培训会,120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","688549","688343","09969","688220","688176","688302","688256","688373","688266","02402","688538","688469","688277","688512","688322","688316","ONC","688165","688280","06160","688702","688561","688192","688221","688327","688443","688197","688387","688515","688382","000690.SH","BK0239"],"gpt_icon":0},{"id":"2548027096","title":"首药控股-U涨5.41% 政策红利与估值压力共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2548027096","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548027096?lang=zh_cn&edition=full","pubTime":"2025-07-01 14:54","pubTimestamp":1751352897,"startTime":"0","endTime":"0","summary":"首药控股-U股价大幅上涨,最新价38.16元/股,涨幅5.41%。资金博弈与估值压力共振首药控股-U近期净流出主要受主力资金波动及市场风格切换影响。此外,公司动态市盈率-26.52倍,市净率7.10倍显著高于行业均值,估值压力放大了短期波动弹性。研发突破与政策红利双轮驱动长期来看,首药控股-U的核心逻辑取决于创新药研发管线进展及商业化兑现能力。2025年医保目录调整首次将商保创新药纳入申报范围,政策红利或加速管线药物获批后的市场渗透。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701145459a4c84b0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701145459a4c84b0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2546627994","title":"首药控股-U早盘跌5.02%创月新低 资金持续流出压制股价","url":"https://stock-news.laohu8.com/highlight/detail?id=2546627994","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546627994?lang=zh_cn&edition=full","pubTime":"2025-06-26 09:43","pubTimestamp":1750902198,"startTime":"0","endTime":"0","summary":"首药控股-U早盘股价大幅下挫,截至09点42分,下跌5.02%,报34.26元/股,创近1个月新低。资金流向主导波动首药控股-U近期股价波动受主力资金流向影响显著。截至6月25日,主力资金累计净流出2272.3万元,近20日净流出天数达12日,显示资金分歧加剧。同时,大盘指数如6月25日上证指数创年内新高,非银金融板块领涨,但化学制药行业整体资金流出,拖累个股表现。基本面支撑前景长期看,首药控股-U股价受基本面因素主导。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094328a71df464&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250626094328a71df464&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2545023004","title":"首药控股-U06月24日主力净流出259.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2545023004","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545023004?lang=zh_cn&edition=full","pubTime":"2025-06-24 15:20","pubTimestamp":1750749656,"startTime":"0","endTime":"0","summary":"06月24日, 首药控股-U股价跌0.03%,报收36.29元,成交金额4361.9万元,换手率1.88%,振幅2.70%,量比0.75。首药控股-U今日主力资金净流出259.7万元,上一交易日主力净流入666.6万元。该股近5个交易日下跌3.59%,主力资金累计净流出301.0万元;近20日主力资金累计净流出2423.9万元,其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624165444a4bb22b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250624165444a4bb22b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688197","BK0239"],"gpt_icon":0},{"id":"2545940624","title":"首药控股-U06月23日主力净流入666.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2545940624","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545940624?lang=zh_cn&edition=full","pubTime":"2025-06-23 15:20","pubTimestamp":1750663241,"startTime":"0","endTime":"0","summary":"06月23日, 首药控股-U股价涨3.83%,报收36.30元,成交金额6310.0万元,换手率2.78%,振幅6.06%,量比1.15。首药控股-U今日主力资金净流入666.6万元,上一交易日主力净流出140.1万元。该股近5个交易日下跌7.73%,主力资金累计净流入82.0万元;近20日主力资金累计净流出2186.9万元,其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623165344a4b88f5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623165344a4b88f5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2544714123","title":"首药控股:拟使用自有资金支付募投项目部分款项并以募集资金等额置换","url":"https://stock-news.laohu8.com/highlight/detail?id=2544714123","media":"公司公告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544714123?lang=zh_cn&edition=full","pubTime":"2025-06-20 16:10","pubTimestamp":1750407029,"startTime":"0","endTime":"0","summary":"首药控股公告,公司拟在募投项目实施期间使用自有资金支付部分款项,并定期以募集资金等额置换。此举旨在提高资金使用效率和运营管理效能,符合相关监管规定,不会影响募投项目的正常实施或损害股东利益。截至2024年12月31日,公司募集资金投入总额为9.993亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620164013a7141ec8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250620164013a7141ec8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2544154674","title":"首药控股-U06月19日遭主力抛售539.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2544154674","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544154674?lang=zh_cn&edition=full","pubTime":"2025-06-19 15:21","pubTimestamp":1750317664,"startTime":"0","endTime":"0","summary":"06月19日, 首药控股-U股价跌4.65%,报收35.44元,成交金额6667.1万元,换手率2.89%,振幅6.08%,量比0.97。首药控股-U今日主力资金净流出539.9万元,上一交易日主力净流出27.9万元。该股近5个交易日下跌17.41%,主力资金累计净流出1846.6万元;近20日主力资金累计净流出3170.6万元,其中净流出天数为13日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619171137a71231e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619171137a71231e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2544133917","title":"首药控股:ALK-TKI双代布局 SY-707上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2544133917","media":"长城国瑞证券有...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544133917?lang=zh_cn&edition=full","pubTime":"2025-06-19 10:38","pubTimestamp":1750300696,"startTime":"0","endTime":"0","summary":"公司二代ALK-TKI 商业价值即将释放,三代ALK-TKI 临床进展顺利。我国ALK-TKI 市场:二代主导,差异化竞争格局显现。首款国产ALK-TKI 恩沙替尼自2020 年11月上市以来持续拓展市场,2024 年已占据7.71%的市场份额。考虑公司二代ALK-TKI——SY-707 上市在即,SY-3505 是目前临床进展最快的国产第三代ALK-TKI,SY-5007 是全球唯一已经进入临床III 期的国产选择性RET-TKI、年内有望提交NDA,当前市值小于测算的公司股权价值,我们首次给予其“增持”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506191049579785da86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506191049579785da86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2544182082","title":"长城国瑞证券给予首药控股增持评级:ALK-TKI双代布局,SY-707上市在即","url":"https://stock-news.laohu8.com/highlight/detail?id=2544182082","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544182082?lang=zh_cn&edition=full","pubTime":"2025-06-19 09:16","pubTimestamp":1750295793,"startTime":"0","endTime":"0","summary":"长城国瑞证券6月18日发布研报称,给予首药控股增持评级。评级理由主要包括:1)聚焦NSCLC小分子创新药领域,同时拥有第二代、三代ALK-TKI;2)公司二代ALK-TKI商业价值即将释放,三代ALK-TKI临床进展顺利;3)我国ALK-TKI市场:二代主导,差异化竞争格局显现;4)SY-5007:研发进度前列的国产选择性RET-TKI,III期临床随访中。文章来源:每日经济新闻长城国瑞证券给予首药控股增持评级:ALK-TKI双代布局,SY-707上市在即","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619092405a4b18a8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250619092405a4b18a8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688197","161027"],"gpt_icon":0},{"id":"2544922509","title":"首药控股-U06月18日主力净流出27.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2544922509","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544922509?lang=zh_cn&edition=full","pubTime":"2025-06-18 15:20","pubTimestamp":1750231256,"startTime":"0","endTime":"0","summary":"06月18日, 首药控股-U股价跌1.25%,报收37.17元,成交金额4197.3万元,换手率1.77%,振幅2.60%,量比0.55。首药控股-U今日主力资金净流出27.9万元,上一交易日主力净流入123.3万元。该股近5个交易日下跌10.91%,主力资金累计净流出471.0万元;近20日主力资金累计净流出2528.1万元,其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618170001a71024e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250618170001a71024e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688197"],"gpt_icon":0},{"id":"2544195111","title":"首药控股:公司高选择性RET抑制剂SY-5007关键性注册Ⅲ期临床试验的主要疗效指标超过预设值","url":"https://stock-news.laohu8.com/highlight/detail?id=2544195111","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544195111?lang=zh_cn&edition=full","pubTime":"2025-06-17 16:42","pubTimestamp":1750149738,"startTime":"0","endTime":"0","summary":"证券之星消息,首药控股(688197)06月17日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,请问我们的公司的创新药SY-5007三期临床结果如何?首药控股回复:尊敬的投资者,您好!公司高选择性RET抑制剂SY-5007关键性注册Ⅲ期临床试验的主要疗效指标(经IRC评估的ORR)超过预设值,主要研究终点已经达到。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025061700024853.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1576","688197","BK1583","BK1141","BK0239"],"gpt_icon":0},{"id":"2544663954","title":"A股创新药企:多家公司研发人员占比突破79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2544663954","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544663954?lang=zh_cn&edition=full","pubTime":"2025-06-17 16:28","pubTimestamp":1750148880,"startTime":"0","endTime":"0","summary":"南方财经6月17日电,2024年A股创新药及研发服务企业年报数据显示,多家公司研发人员占比突破79%。具体数据如下:普蕊斯:研发人员占比95.92%,研发人员数量4,236人;益方生物-U:研发人员占比91.35%,研发人员数量169人;首药控股-U:研发人员占比88.76%,研发人员数量158人;万邦医药:研发人员占比86.19%,研发人员数量412人;阳光诺和:研发人员占比84.70%,研发人员数量1,318人;睿智医药:研发人员占比79.22%,研发人员数量1,437人","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617162858951febf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250617162858951febf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688621","688382","159982","159992","688197","BK0239","399300"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753892263558,"stockEarnings":[{"period":"1week","weight":-0.0257},{"period":"1month","weight":0.2811},{"period":"3month","weight":0.4787},{"period":"6month","weight":0.5785},{"period":"1year","weight":0.3417},{"period":"ytd","weight":0.5134}],"compareEarnings":[{"period":"1week","weight":0.0078},{"period":"1month","weight":0.0542},{"period":"3month","weight":0.1008},{"period":"6month","weight":0.1105},{"period":"1year","weight":0.2482},{"period":"ytd","weight":0.077}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"首药控股(北京)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"4297人(较上一季度增加4.75%)","perCapita":"14895股","listingDate":"2022-03-23","address":"北京市大兴区北京经济技术开发区荣华中路10号1幢A座22层2205","registeredCapital":"14871万元","survey":" 首药控股(北京)股份有限公司的主营业务是肿瘤和糖尿病药物的研发。公司的主要产品是技术开发及服务。","listedPrice":39.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"首药控股(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供首药控股(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"首药控股,688197,首药控股股票,首药控股股票老虎,首药控股股票老虎国际,首药控股行情,首药控股股票行情,首药控股股价,首药控股股市,首药控股股票价格,首药控股股票交易,首药控股股票购买,首药控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"首药控股(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供首药控股(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}